Instructions for Cereton (Choline alfoscerate) solution 250 mg
Cereton (Choline alfoscerate) solution 250 mg
English product name
Cereton
Release Form
250 mg/1 ml: amp. four ml 3, 5, 6 or 10 pcs.
Description Cereton
The solution for in/in and in/m injection is transparent, colorless.
1 ml 1 amp.
choline alfoscerate polyhydrate (in terms of anhydrous choline alfoscerate) 250 mg 1000 mg
Auxiliary substances: water d/i.
ATC codes
N07AX02 Choline alfoscerate
Clinical-pharmacological groups / Group affiliation
Nootropic drug. Central Action Cholinomimetic
Active substance
choline alfoscerate
Pharmaco-therapeutic group
Nootropic agent
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.
Best before date
The shelf life is five years.
Pharmacological effect Cereton
Nootropic drug. Central cholinovulator containing 40.5% metabolically protected choline.
Metabolic protection promotes the release of choline in the brain. Provides acetylcholine and phosphatidylcholine synthesis in neuronal membranes, improves blood flow and enhances metabolic processes in the CNS, activates the reticular formation.
Testimony Cereton
- acute and recovery periods of severe head trauma and ischemic stroke,
- recovery period of hemorrhagic stroke,
- occurring with focal hemispheric symptoms or symptoms of brain stem lesions;
- psychoorganic syndrome amid degenerative and involutive brain changes;
- cognitive disorders (impairments in thought function,
- memory, confusion,
- disorientation,
- decreased motivation, initiative,
- and ability to focus), including dementia and encephalopathy;
- an old pseudo-melancholy.
Method of use, course and dosage Cereton
In the case of acute conditions, 1,000 mg (one ampoule) per day is injected into/into (slowly) or deeply into/into (slowly) the vessels for ten to fifteen days.
- Nosology (ICD codes)
- F01
- Vascular dementia
- F03
- Dementia unspecified
- F07
- Personality and behavioural disorders caused by disease, damage or brain dysfunction
- G92
- Toxic encephalopathy
- G93.4
- Encephalopathy unrefined
- I63
- Brain infarction
- I67.4
- Hypertensive encephalopathy
- I69
- Effects of cerebrovascular disease
- S06
- Intracranial injury
- T90
- Effects of head injuries
